SUSAN MORPHIS: Open Payments
NPI 1952825572 · DELHI, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,007 in 53 payments from 11 companies in 2025. Trend: 2023 $1,260 · 2024 $817 · 2025 $1,007
Food & beverage: $1,007
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 13 | $348 |
| Otsuka America Pharmaceutical, Inc. | 10 | $171 |
| ABBVIE INC. | 11 | $144 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $117 |
| Alkermes, Inc. | 3 | $49 |
| E.R. Squibb & Sons, L.L.C. | 3 | $46 |
| Corium, LLC | 3 | $44 |
| Neurocrine BioSciences, Inc. | 1 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
Products named: Auvelity, REXULTI, VRAYLAR, CAPLYTA, ARISTADA, COBENFY, Azstarys, INGREZZA.
Industry payments across LA — which companies pay providers there.
